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A survey was undertaken to determine the current practice in the Yorkshire Health Region for the assessment 
and provision of home nebulizers for adults with chronic obstructive pulmonary disease (COPD). A detailed 
postal questionnaire on assessment methods was sent to each of the 22 consultant physicians in respiratory 
medicine. The 17 consultants who also organized the adult home nebulizer service for their health district were 
asked about the services offered and funding for the service. Replies were received from all consultants. 
All physicians use objective measurement for assessing patients for home nebulizer therapy, but there is a 
variable emphasis on laboratory studies, walking distance and home trials with peak flow measurements. The 
majority (86%) incorporate a home trial into their assessment. Many physicians also take into account 
subjective response to nebulized bronchodilators. 
There is considerable variation in the provision and funding of home nebulizer services. Those districts with 
a coordinated service appear to offer a more comprehensive service. 
A consensus on nebulizer provision, with recommendations for minimum levels of provision in each health 
district, should result in a more uniform delivery of service. 
Introduction 
Patients with chronic obstructive pulmonary dis- 
ease (COPD) are often severely disabled by dysp- 
noea. Response to standard doses of inhaled 
bronchodilators is often limited but larger doses may 
produce further bronchodilatation (1) which may be 
maintained with prolonged use (2). Around one 
quarter of patients with COPD will require high dose 
therapy (e.g. >l mg inhaled salbutamol) to achieve 
optimal bronchodilatation (3). 
The methods described for selecting adults with 
COPD for home nebulizer therapy are variable. 
These have included tests of short term reversibility 
to bronchodilators (4) and functional response to 
nebulized drugs (e.g. improvement in walking dis- 
tance). Recent studies have highlighted the lack of 
predictive value of these acute tests for longer term 
benefit from a home nebulizer, and have shown that 
home trials with peak expiratory flow (PEF) moni- 
toring and symptom scores are the optimal method 
of assessment (5-7). The British Thoracic Society 
guidelines recommend an initial 3-week home trial of 
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nebulizer therapy for adults with severe chronic 
asthma, with PEF and symptom score monitoring 
during this period (8). The greater predictive value of 
home trials should improve the cost-effectiveness of 
home nebulizer provision in adults with COPD. 
The provision of home nebulizers for patients with 
COPD has been steadily increasing in the U.K. (9). 
Nebulized P-agonists with ipratropium given four 
times daily costs around El100 annually per patient 
in the U.K. The costs of a loan and repair service are 
additional to this (10). 
Preliminary enquiries within the Yorkshire Health 
Region suggested considerable variation in the level 
of service offered between different districts. A survey 
was therefore undertaken to determine the current 
practice within each district for the assessment, pro- 
vision and funding of adult home nebulizer services. 
The aims of the study were to identify major varia- 
tions in practice, and to relate this to the emerging 
consensus on assessment methods and the need for 
adequate funding for such a service. 
Methods 
A detailed postal questionnaire was sent to each of 
the 22 consultant physicians with an interest in 
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respiratory medicine within the Yorkshire Health 
Region of the U.K. All were asked about the 
methods of assessment they used for selecting 
patients suitable for home nebulizer therapy. The 17 
physicians who organized the adult home nebulizer 
service for their health district were also asked about 
the services offered and the financial provision. Ser- 
vices for children and for patients with cystic fibrosis 
were excluded. 
Results 
Replies were received from all 22 physicians. 
Twenty-one assess patients for home nebulizers, and 
17 are directly involved with the provision of a 
district-wide home nebulizer service. 
ASSESSMENT 
Eighteen of the 21 (86%) physicians who assess 
patients for home nebulizers use laboratory pul- 
monary function tests as part of their assessment 
(Fig. 1). Of these, three (17%) use baseline tests only 
(FEV,, FVC, PEF). Three physicians measure acute 
bronchodilator response (FEV,, FVC, PEF) follow- 
ing nebulized drugs, and 12 (67%) compare the 
bronchodilator responses of nebulized drugs to the 
use of metered dose inhalers (MDI) with large volume 
spacers. Ten physicians (48%) incorporate walking 
tests into their assessments, but none use this as the 
only method. Three physicians rely solely on a home 
trial of nebulizer assessed by symptom improvement 
and home peak flow monitoring, although 15 others 
(71%) employ a trial of home use as part of their 
assessment. Two physicians incorporate a placebo 
arm to a home nebulizer trial, and one physician also 
uses a cross-over comparison with an equivalent 
dose delivered via an MD1 with a spacer. Duration of 
home trials varies from 1 week to 2 months, the 
commonest being 1 month. Criteria for a positive 
assessment vary considerably. Four physicians use 
objective criteria alone and 17 take into account the 
symptomatic response to a home nebulizer trial. 
Initial tuition for patients is available in all but one 
district. This is usually provided by the chest clinic 
nurse (6) pulmonary function technician (5) or 
physiotherapist (4) but occasionally by the phar- 
macy (1) the consultant (2) or the ward staff (2). Five 
districts have a service for visiting patients at home 
by the respiratory support nurse (4) or pulmonary 
function technician (1). 
COSTS 
The costs of the different assessment methods vary 
between districts, but have been estimated in one 
Walking Laboratory 
distance studies 
Fig. I Home nebulizer assessment. A Venn diagram 
showing the use of laboratory studies, walking distance 
and home trials by the 21 respiratory physic&s in the 
Yorkshire Health Region who assess patients for home 
nebulizer therapy. 
district to be approx. f15.00 for laboratory reversi- 
bility studies, g15.00 for walking distance, and E78.00 
for a 4-week home nebulizer trial (2 weeks spacer vs. 
2 weeks nebulizer therapy). 
PRESCRIBING 
Prescribing information was available from 19 
physicians. All use a B-agonist, 17 preferring salbuta- 
mol to terbutaline (90%). Three physicians (16%) 
used only 2.5 mg nebules, the others varying their 
prescription (37%) or using 5 mg doses (47%). 
One physician occasionally uses 1 mg doses. Two 
physicians do not prescribe ipratropium. A further 7 
(37%) use it only in a proportion of their patients. 
Dose frequency ranged from 2-5 times daily, the 
commonest being a qds regimen. 
PROVISION 
Each of 17 health districts has one respiratory 
physician who is directly’ concerned with home 
nebulizer provision. 
Eleven of these (65%) have a centralized service 
which is coordinated by a wide variety of staff. Clinic 
nursing staff (3 districts) and pulmonary function 
technicians (3 districts) are frequently responsible for 
running the service, whilst in some districts the 
physiotherapist (1 district), pharmacy (1 district), a 
ward clerk (1 district) or the consultant (1 district) 
are involved. In one district there is no specific person 
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Fig. 2 The provision of services for home nebulizer therapy in all 17 districts within the Yorkshire Health Region. The 
chart shows how many districts provide each aspect of a home nebulizer service. n , Centralized n = 11. fZ, Non-centralized 
n=6). 
in charge. Only one district provides payment (1 h) 
for running the service. Six districts allow other 
physicians independent access, and four offer this 
facility to paediatricians. All 11 districts offer loan of 
compressors and a repair service, 10 providing a 
replacement during repair (Fig. 2). Ten (91%) supply 
masks and tubing and three routinely supply nebu- 
lized drugs. Three districts provide an emergency 
out-of-hours replacement service. Compressors are 
routinely recalled for maintenance in eight districts, 
with a further two districts servicing machines on 
return from loan. A total of 11 compressor types are 
used, the commonest being the Portaneb 50 and the 
Medix traveller (Table 1). There is considerable 
Table I Numbers and types of compressors used in 
Yorkshire (approx.) (numbers include those used for all 
adult respiratory disease, e.g. asthma, cystic fibrosis) 
Type Total no. 
Portaneb 50 1043 
Medix traveller 339 
Medix compact 66 
Baird inspiron 50 
Medix minor II 48 
Devilbis ultrasound 31 
Compact traveller 30 
Bennett TV4+ 28 
Park inhalerboy 20 
Pulmo-aide 4 
Easyair footpump 2 
variation between the 11 districts in the number of 
compressors provided on loan ranging from four to 
213 per 100 000 population (Fig. 3), with an esti- 
mated total of 2000 provided in the Yorkshire Health 
Region. 
Six districts have no centralized adult home nebu- 
lizer service. Three of these have no service at all, and 
one offers a repair service for patients’ own compres- 
sors. In the two districts that provide compressors, 
individual consultants do so on an ‘ad hoc’ basis. In 
both cases they also offer repair and replacement 
facilities. 
FUNDING 
Only 11 of the 21 consultants felt able to prescribe 
a nebulizer to all patients they felt required one. Only 
eight of the 17 districts (47%) receive Health Author- 
ity funding for nebulizer provision and one receives 
funding only for spares and servicing. Some patients 
are asked to buy their own compressor or to contrib- 
ute in five of the 11 (45%) districts providing a 
centralized service. Local charity funding is sought in 
seven districts, two relying solely on this source of 
funding (Fig. 4). 
None of the six districts without a centralized 
service receives direct funding. Other sources (trust 
funds, charities) are sometimes used but three dis- 
tricts are unable to provide any assistance except 
through VAT exemption. Only four districts reported 
no difficulties in funding. 
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Fig. 3 The number of compressors provided per 100 000 population in each of the 11 districts which offer a centralized 
home nebulizer service (see text for details). 
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Fig. 4 Funding for home nebulizer services. A pie chart showing the major source of funding for the home nebulizer 
service in all 17 districts of the Yorkshire Health Region. Two districts have more than one major source of funding. 
Discussion ASSESSMENT 
Careful assessment of patients with severe COPD 
This study highlights the uncertainties and difficul- should allow selection of patients with minimal 
ties concerning the assessment and provision of home reversibility to standard doses of bronchodilators, 
nebulizers for adults with COPD. who will benefit from a home nebulizer. Some 
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authors have questioned the need for home nebuliz- 
ers, given that similar short term bronchodilatation 
can be achieved using high dose bronchodilators via 
a spacer device (11). However, most studies that have 
shown no additional benefit from a home nebulizer 
included patients with asthma, and there is good 
evidence that home nebulizer therapy benefits a 
proportion of patients with more severe COPD who 
have minimal acute bronchodilator reversibility on 
laboratory testing (5-7,12). The mainstay of assess- 
ment should be a home trial of at least 1 week 
duration for each drug regimen, with PEF monitor- 
ing and symptom scores (13). About one quarter of 
patients will benefit in terms of a significant increase 
in peak flow and improvement in symptom scores 
(5-7,14). In such a disabled group of patients, minor 
improvements in exercise tolerance often have a large 
impact on their quality of life. 
Laboratory tests of reversibility, including com- 
parisons with other methods of delivery, should not 
be used alone to select patients for home nebulizer 
therapy, but rather as a guide to severity of airflow 
obstruction. Additionally, administration of the first 
doses of nebulized bronchodilators in hospital will 
exclude any initial adverse effects (5). 
Although all physicians in this study used objec- 
tive methods of assessment, there was a variable 
emphasis on laboratory studies, walking distance 
and home PEF recordings, records of subjective 
benefit, and comparisons at home between nebuliz- 
ers and MDIs with spacers (12). However, there 
appears to be an increasing use of home trials of 
nebulizer therapy measuring PEF and subjective 
responses, reflecting the greater predictive value of 
these compared with laboratory-based studies and 
walking distance (6,7,14). Eighteen of the 21 (86%) 
physicians use home trials as part of their assess- 
ment. This trend should allow more accurate 
identification of patients likely to benefit from 
therapy. 
It is possible that some of the beneficial effects of a 
home nebulizer are not due to a measurable bron- 
chodilator effect and may include changes such as 
improved mucociliary clearance, humidification of 
the airways and changes in small airway calibre that 
are not easily detectable using simple spirometric 
techniques. Peak flow responses during a home trial 
will only identify responders in physiological terms, 
and subjective response in patients with severe COPD 
may be important in patients with minimal objective 
(i.e. peak flow) benefit. Most physicians in this study 
acknowledge this by taking into account subjective 
response (i.e. symptom scores) to a home trial in 
deciding whether to recommend a home nebuhzer. 
However, adding a placebo (saline) comparison dur- 
ing a home trial may help in identifying patients with 
true symptomatic benefit from nebulized bronchodi- 
lators (6,7,14), and we also recommend a period of 
home PEF recording using an MD1 with a spacer 
(12). 
PROVISION AND FUNDING 
There is wide variation in the provision and 
funding of home nebulizer services for adults in 
Yorkshire. In most districts, considerable uncertainty 
exists about future arrangements. 
A centralized service should offer more compre- 
hensive facilities for new patients and more reliable 
information on usage, capital and running costs. The 
allocation of a nurse, pulmonary function technician, 
pharmacist or physiotherapist to coordinate supply, 
tuition, home support and repair/maintenance ser- 
vices would be the best means of providing such a 
centralized service. Purchasers should be made aware 
of the need for each district to offer a service for the 
provision, repair and replacement of home nebuliz- 
ers. Providers should seek adequate funding to meet 
the costs of equipment purchase, a maintenance/ 
repair service and funding of such staff. Such costs 
should be included in contracts for providing general 
respiratory services. 
Given such enormous variation in nebulizer provi- 
sion both between districts and between physicians, 
and the costs associated with this treatment, it is 
essential to establish the cost-effectiveness of home 
nebulizer therapy. A prospective study is needed to 
examine the impact of therapy on quality of life, 
hospital admission rates and survival, rather than 
physiological measurement alone. 
Despite the increasing use of home nebulizers 
in the treatment of COPD, their use is not without 
risk, and patients who are being considered for this 
form of therapy should be assessed by a respiratory 
physician. 
Notes 
1. This study was conducted prior to the circu- 
lation of a letter from The Department of Health 
concerning equipment provision, indicating that 
NHS consultants may prescribe a home nebulizer as 
part of NHS treatment and when they do so no 
charge can be made. Health authorities should 
meet maintenance costs of the equipment they 
supply. 
2. A copy of the questionnaire used in the survey is 
available on request. 
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